IP Library Granted Patent US 8,501,176
Granted Patent B2
US 8,501,176 · App. 13/177,221 · Granted Aug 6, 2013

Methods of reducing eosinophil levels

Inventors: Masamichi Koike (West Windsor, NJ); George L. Spitalny (Yardley, PA); Alistair Wheeler (Northborough, MA); Barbara White (Finksburg, MD)
Assignees: MedImmune, LLC; BIOWA, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,176
App. No.
13/177,221
Granted
Aug 6, 2013
Kind
B2
Abstract

The present invention relates to a method of reducing the numbers of eosinophils in a human subject comprising administration to a subject an IL-5R binding molecule that comprises (a) a region that specifically binds to the IL-5R and (b) an immunoglobulin Fc region. In a specific embodiment, a method of the invention reduces the number of eosinophils in blood, bone marrow, gastrointestinal tract (e.g. esophagus, stomach, small intestine and colon), or lung.

Claims (8)

1. A method of reducing the numbers of peripheral blood eosinophils in a human subject comprising parenterally administering to said subject between about 0.01 to about 0.25 mg/kg of an anti-IL5R antibody comprising the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO:3 and comprising an immunoglobulin Fc region comprising no fucose, wherein the administration of the antibody reduces the number of peripheral blood eosinophils from the human subject's circulation below the limit of detection and the circulating eosinophil count level remains below detection for at least about 28 days after dosing of the antibody.

2. The method of claim 1 , wherein the reduction of eosinophils takes place within the first 48 hours after administration.

3. The method of claim 1 , wherein the reduction of eosinophils is reversible.

4. The method of claim 1 , wherein said subject's pre-administration absolute eosinophil count is between about 50 and about 500 eosinophils/mm 3 .

5. The method of claim 1 , wherein said subject's pre-administration absolute eosinophil count is about 25, about 50, about 75, about 100, about 125, about 150, about 175, about 200, about 225, about 250, about 275, about 300, about 325, about 350, about 375, about 400, about 450, about 475 or about 500 eosinophils/mm 3 .

6. The method of claim 1 , wherein said subject's post-administration absolute basophil count is reduced by at least about 5, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70 basophils/mm 3 .

7. The method of claim 1 , wherein said reduction in eosinophils leads to a reduction in asthma symptoms.

8. The method of claim 1 , wherein said reduction in eosinophils leads to a reduction in COPD symptoms.

Assignments (5)
CHANGE OF NAME Recorded Dec 3, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 051171/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2019
From: BIOWA INC
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 049275/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2016
From: MEDIMMUNE, LLC
To: ASTRAZENECA AB
Reel/Frame 039257/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2014
From: KOIKE, MASAMICHI; SPITALNY, GEORGE L.; WHEELER, ALISTAIR
To: BIOWA
Reel/Frame 032983/0548 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2014
From: WHITE, BARBARA
To: MEDIMMUNE, LLC
Reel/Frame 032983/0693 →
Continuity (6)
Continuation 12600017
Provisional Application 60924422 · May 14, 2007
Provisional Application 60924832 · Jun 1, 2007
Provisional Application 60935005 · Jul 20, 2007
Provisional Application 61064612 · Mar 14, 2008
Related Publication 20120148575A1 · Jun 14, 2012